CTRI/2021/11/037702招募中3 期
Minimal residual disease guided therapy in newly diagnosed multiple myeloma. - Safetyof MRD guided VRd consolidation
Intramural grant of Tata Memorial Center Mumbai0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.patient with histologically proven PCNSL
- •2. Received methotrexate based induction therapy
- •3. Radio logical consolidation therapy after achieving CR
- •5.Age >18 years
- •6.PS >2 after the completion of consolidation therpy
- •7.Adequate bone marrow function with absolute leukocytes >2000mm3,neutrophil count ANC >1000/mm3.haemoglobin >8g/dl and platelets >100000/mm3
- •8.Adecute liver function with serum SGOT/AST or SGPT/ALT <3.0Xupper limit of Normal ULN;bilirubin <1.5XLNS
- •9.Creatinineclearance >30ml/min.Patients with calculated ceratine cleearance between 30 and 60 ml/min lenalidomide dose will be adjusted as follows(10 mg oncedalily)
- •10.Able to take aspirin(75mg) daily as prophylactic anticoagulant
- •11.Able to understand the teratogenicity
- •12.Men and women of child bearing age should agree to use reliable contraception
- •13. Neuropathy of >grade 2 severity
- •14.Able to understand and sign inform consent
排除标准
- •Diagnosis of sleep apnea or any other chronic respiratory disease
- •Any acute or chronic condition that would limit the ability of the patient to participate in the study
- •Refusal to give informed consent
研究者
相似试验
尚未招募
不适用
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNon-Small Cell Lung CancerNCT06709274Guangdong Association of Clinical Trials342
已完成
不适用
Prospective evaluation of minimal residual disease in acute myeloid leukemia using TIM-3 as a leukemia markeracute myeloid leukemiaJPRN-UMIN000030977Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine50
进行中（未招募）
不适用
Eradication of Minimal Residual Disease (MRD) in patients with Chronic Lymphocytic Leukaemia (CLL) with Alemtuzumab: A Phase II Study - UKCLL07Chronica Lymphocytic Leukaemia (CLL)EUCTR2006-000053-22-GBeeds Teaching Hospitals NHS Trust54
已完成
不适用
Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemiaacute myeloid leukemia10024324AMLNL-OMON38951Vrije Universiteit Medisch Centrum31
进行中（未招募）
不适用
Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid LeukaemiaMinimal residual disease after allogeneic stem cell transplantation in Acute Myeloid LeukaemiaMedDRA version: 15.1Level: LLTClassification code 10001941Term: AMLSystem Organ Class: 100000004864EUCTR2013-000238-37-NLVU University medical center